Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals

Inclusion Criteria Patients must have: * HIV positivity confirmed by Western blot. * CD4 count of 100 - 500 cells/mm3 on a morning draw within 3 weeks prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: * Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma of the cervix, or nondisseminated Kaposi's sarcoma. * Hemophilia or other clotting disorders. * Major organ allograft. * Significant cardiac, hepatic, renal, or CNS disease. Prior Medication: Excluded: * Antiretroviral agents within 2 months prior to study entry. * Known anti-HIV medication within 60 days prior to study entry. * Prior immunomodulators (e.g., systemic steroids, interferons, or interleukins) or other chemotherapy. Prior Treatment: Excluded: * Prior radiation therapy. Active substance abuse.